Vyriad is a clinical stage biopharmaceutical company.
Vyriad has raised $25.0M in total funding. The most recent round was Series B. The last funding was announced in December 2025.
Vyriad's investors include Mayo Clinic, Regeneron, Mirae Asset, Southeast Minnesota Capital Fund, Harry H. Stine.
Vyriad is headquartered in Rochester, United States.
Vyriad is a clinical stage biopharmaceutical company.
Vyriad is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Vyriad — Funding & Investors." VCBacked, December 23, 2025, https://www.vcbacked.co/company/vyriad. Accessed July 21, 2026.
VCBacked. (2025). Vyriad — Funding & Investors. Retrieved July 21, 2026, from https://www.vcbacked.co/company/vyriad
{{cite web |title=Vyriad — Funding & Investors |url=https://www.vcbacked.co/company/vyriad |website=VCBacked |access-date=July 21, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated